Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses VEGF TKI/immunotherapy combinations will become the standard of care soon at the 2017 Kidney Cancer Association symposium in Miami, FL.
VEGF TKI immunotherapy combinations will become the standard of care soon
